Orphan drug designation granted in the EU for pridopidine in amyotrophic lateral sclerosis (ALS)

Pridopidine is a selective Sigma-1 receptor agonist, currently being assessed in the HEALEY ALS Platform trial, with results expected in 2022. Orphan designation was granted by virtue of the rarity of the disease and the drug’s potential for preservation of motor function.

Source:

Biospace Inc.